Press release
Major Growth Driver Identified in 2025 Pulmonary Arterial Hypertension Market: Elevated Prevalence Of Pulmonary Arterial Hypertension (PAH) Driving Market Growth
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for pulmonary arterial hypertension has seen robust expansion in recent years. It is forecasted to increase from $8.47 billion in 2024 to $9.24 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.1%. Factors such as heightened awareness and detection of pulmonary arterial hypertension (PAH), growth in healthcare spending, an aging population, expansion of treatment options for pulmonary arterial hypertension, and increased research and development activities in the field of pulmonary hypertension have contributed to the growth experienced during the historical period.
Pulmonary Arterial Hypertension Market Size Forecast: What's the Projected Valuation by 2029?
Expectations are high for the pulmonary arterial hypertension market to experience robust growth in the upcoming years. The market size is projected to expand to $12.97 billion in 2029, with a compound annual growth rate (CAGR) of 8.8%. This growth within the projected timeframe can be credited to several factors including the rise in adoption of innovative therapies for pulmonary arterial hypertension, a heightened emphasis on early identification and diagnosis, a burgeoning pipeline of PAH drugs and healing procedures, precision medicine's role in PAH treatment, and the development of healthcare infrastructure in rising markets. Prominent trends predicted for this period comprise advancements in medical imaging and diagnostic technologies, alliances and partnerships for drug development, patient-focused methodologies in managing pulmonary arterial hypertension, and an amplified utilization of combination therapy.
View the full report here:
https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report
What Are the Drivers Transforming the Pulmonary Arterial Hypertension Market?
The rise in instances of pulmonary arterial hypertension (PAH) disease is fuelling the expansion of the PAH market. The surging rate of PAH diseases and the associated hospital admissions for treatment are anticipated to stimulate demand for corresponding medicines throughout the projected timeline. As per research conducted by the National Organization for Rare Disorders, Inc., fresh incidents of PAH are calculated to emerge in one to two persons per million every year in the USA, translating to 500-1000 new cases annually, and Europe is anticipated to reveal comparable rates of occurrence.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp
What Long-Term Trends Will Define the Future of the Pulmonary Arterial Hypertension Market?
Leading businesses in the pulmonary arterial hypertension market are pioneering new products like Winrevair to bolster the treatment alternatives and outcome for patients afflicted with this critical condition. For instance, Merck & Co. Inc, an American multinational pharmaceutical firm, unveiled Winrevair in March 2024 for treating adults suffering from pulmonary arterial hypertension. The therapy, the first to be approved by the US-based Food and Drug Administration (FDA) targets activin signaling for treating PAH. This groundbreaking treatment achieves its results by reinstating the equilibrium between pro- and anti-proliferative cues, ultimately regulating the vascular cell proliferation pertinent to PAH. Consequently, it paves the way for a novel treatment category for this ailment.
Which Segments in the Pulmonary Arterial Hypertension Market Offer the Most Profit Potential?
The pulmonary arterial hypertension market covered in this report is segmented -
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=5954&type=smp
Which Firms Dominate the Pulmonary Arterial Hypertension Market by Market Share and Revenue in 2025?
Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.
Which Regions Offer the Highest Growth Potential in the Pulmonary Arterial Hypertension Market?
North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5954
This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Major Growth Driver Identified in 2025 Pulmonary Arterial Hypertension Market: Elevated Prevalence Of Pulmonary Arterial Hypertension (PAH) Driving Market Growth here
News-ID: 4081920 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
